Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. LECIGIMON (lévodopa/ carbidopa/ entacapone)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

LECIGIMON (lévodopa/ carbidopa/ entacapone)

Medicine - Posted on Jan 09 2023
Active substance (DCI)
  • lévodopa
  • carbidopa
  • entacapone
history (2)
  • 12/14/22

    LECIGIMON (lévodopa / carbidopa / entacapone) - Maladie de Parkinson

    Key points Approval of reimbursement for the treatment of advanced-stage Parkinson’s disease with motor fluctuations and hyp...
    CAV :
    54321
    icône flèche
  • 3/30/22

    LECIGIMON (lévodopa/ carbidopa/ entacapone) - maladie de Parkinson à un stade avancé

    Key points Unfavourable opinion for reimbursement in the treatment of advanced Parkinson's disease with severe motor fluctua...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • N04BA03
Manufacturer
EG LABO - LABORATOIRES EUROGENERIC
Presentation

LECIGIMON 20 mg/5 mg/20 mg par ml, gel intestinal
Boite de 7 cassettes polyprolène de 47 ml (CIP : 34009 302 356 1 4)

All our publications
    Central nervous system diseases Drug therapy Geriatrics Neurodegenerative diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNrFmF1v2jAUhu/5FVHuk/BRaDsFqo21G1KrMVq0aTeVSQ5gZuz02KZ0v34OoR2tErU1dXcHsfP62Of48RvHJ+sl81aAkgre9Rth3feAJyKlfNb1x1dnwZF/0qvFC7IiO90Ow3rYaPpewoiUXT9vDSdAuAx/Xpx/BvM+oN+rebGYLCBRj/ppRVn4lcj5BcnyPl68EjT1lqDmIu36mVabp14sFZooercCf8uMJBBH2ye7rYvrg93ncZSLvUBVS8BzwmelosCtNBONCFz1iYKZwLuKeFtW2lSOQAqNCQyJmg9RrGgKaekQU8IkWA0yvU0vAVcMVD5IqXi0SJbSSpwsyHoEN4PyoD+a1r5aq6AeNA7bzc5B57DZOW7bLRbuLFV5Fswkouy61WrVjzqNCHjEIKEzuhQ8YLASqchIFCQEJ7T4adJKEpIJDpbZGwpUhDnKG5X9x6XnaByEm2frI6UyY+QuXMjMdqkIEtMMaADhbiL5DK7QIIuZNXuizzVj0SujHm+B4ijinFd9obmq4MrZyHYh+oIrWFdn1A6Far2tRQry7WT/PNmADw1DPWE0sYWewZIGqcajQTXz3hcXn4iEMbrjxQ/KU3Er355Du3l3FH22QWmpaIZp47p5bJLUbltvs18mbRWn1KlGkUFkCEXlPuAZ8KnYFzmmbsul7qv2HQt246ZEQhhU+KnAkk+mUu/tn7O94G6fFQ2lol9Or2wL6LsGvLvc/C2Vpmn3IfV28HZxIphyrQz89cVfMMCJ09ZYzpa5Upn8EEVzIgNJzAqFU/wPJ8POce3uK8CJJyg8UkFXR6FPimPz5fmz3YPPOYZ9XfD2/a3bLh1DoYY98lDg2hlUB6dvz+l/FthZ2MNHXHE3zMauEkUFd2WS9KTcIe11Mpi88jM0cPg2ndKKG5nKuoyj4jaoV4uj/CaoV/sLvBUVAA==
p7rvzGsd8Tw8ESbF